Cardioprotection for percutaneous coronary intervention - Reperfusion quality as well as quantity

International Journal of Cardiology

Volumn 177, Issue 3, 2014, Pages 786-793

  Giblett, Joel P ^a   West, Nick E J ^a   Hoole, Stephen P ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

Cardioprotection; Ischaemia reperfusion injury; Ischemic conditioning; Myocardial infarction; Percutaneous coronary intervention

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CALCIUM; CYCLOSPORIN; CYCLOSPORIN A; G PROTEIN COUPLED RECEPTOR; GLYCERYL TRINITRATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RANOLAZINE; CARDIOTONIC AGENT;

CALCIUM CELL LEVEL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); ENZYME ACTIVATION; GLUCOSE METABOLISM; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE METABOLISM; HEART MUSCLE REPERFUSION; HEART PROTECTION; HUMAN; INDUCED HYPOTHERMIA; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; MYOCARDIAL REPERFUSION INJURY; PHYSIOLOGY; PROCEDURES;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; PERCUTANEOUS CORONARY INTERVENTION; SIGNAL TRANSDUCTION;

EID: 84920053359     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.10.041     Document Type: Review

References (106)

1. K.A. Reimer, J.E. Lowe, M.M. Rasmussen, and R.B. Jennings The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs Circulation 56 1977 786 794
2. H.R. Andersen, T.T. Nielsen, K. Rasmussen, L. Thuesen, H. Kelbaek, and P. Thayssen A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction N. Engl. J. Med. 349 2003 733 742
3. D.S. Menees, E.D. Peterson, Y. Wang, J.P. Curtis, J.C. Messenger, and J.S. Rumsfeld Door-to-balloon time and mortality among patients undergoing primary PCI N. Engl. J. Med. 369 2013 901 909
4. S.P. Hoole, P.M. Heck, P.A. White, P.A. Read, S.N. Khan, and N.E. West Stunning and cumulative left ventricular dysfunction occurs late after coronary balloon occlusion in humans insights from simultaneous coronary and left ventricular hemodynamic assessment JACC Cardiovasc. Interv. 3 2010 412 418
5. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N. Engl. J. Med. 357 2007 1121 1135
6. K. Matsumura, R.W. Jeremy, J. Schaper, and L.C. Becker Progression of myocardial necrosis during reperfusion of ischemic myocardium Circulation 97 1998 795 804
7. D.R. Hunter, and R.A. Haworth The Ca2 +-induced membrane transition in mitochondria. I. The protective mechanisms Arch. Biochem. Biophys. 195 1979 453 459
8. E.J. Griffiths, and A.P. Halestrap Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion Biochem. J. 307 Pt 1 1995 93 98
9. F. Di Lisa, R. Menabo, M. Canton, M. Barile, and P. Bernardi Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD + and is a causative event in the death of myocytes in postischemic reperfusion of the heart J. Biol. Chem. 276 2001 2571 2575
10. G. Kroemer, B. Dallaporta, and M. Resche-Rigon The mitochondrial death/life regulator in apoptosis and necrosis Annu. Rev. Physiol. 60 1998 619 642
11. D.J. Hausenloy, S.B. Ong, and D.M. Yellon The mitochondrial permeability transition pore as a target for preconditioning and postconditioning Basic Res. Cardiol. 104 2009 189 202
12. K. Imahashi, C. Pott, J.I. Goldhaber, C. Steenbergen, K.D. Philipson, and E. Murphy Cardiac-specific ablation of the Na +-Ca2 + exchanger confers protection against ischemia/reperfusion injury Circ. Res. 97 2005 916 921
13. E.J. Griffiths, C.J. Ocampo, J.S. Savage, G.A. Rutter, R.G. Hansford, and M.D. Stern Mitochondrial calcium transporting pathways during hypoxia and reoxygenation in single rat cardiomyocytes Cardiovasc. Res. 39 1998 423 433
14. J.L. Zweier, and M.A. Talukder The role of oxidants and free radicals in reperfusion injury Cardiovasc. Res. 70 2006 181 190
15. R.K. Kharbanda Cardiac conditioning: a review of evolving strategies to reduce ischaemia-reperfusion injury Heart 96 2010 1179 1186
16. J. Vinten-Johansen Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury Cardiovasc. Res. 61 2004 481 497
17. R.L. Engler, M.D. Dahlgren, D.D. Morris, M.A. Peterson, and G.W. Schmid-Schonbein Role of leukocytes in response to acute myocardial ischemia and reflow in dogs Am. J. Physiol. 251 1986 H314 H323
18. R.A. Kloner, C.E. Ganote, and R.B. Jennings The "no-reflow" phenomenon after temporary coronary occlusion in the dog J. Clin. Invest. 54 1974 1496 1508
19. C.E. Murry, R.B. Jennings, and K.A. Reimer Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74 1986 1124 1136
20. D.M. Yellon, and J.M. Downey Preconditioning the myocardium: from cellular physiology to clinical cardiology Physiol. Rev. 83 2003 1113 1151
21. E. Deutsch, M. Berger, W.G. Kussmaul, J.W. Hirshfeld Jr., H.C. Herrmann, and W.K. Laskey Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features Circulation 82 1990 2044 2051
22. D.J. Hausenloy, and D.M. Yellon New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway Cardiovasc. Res. 61 2004 448 460
23. A.B. Stein, X.L. Tang, Y. Guo, Y.T. Xuan, B. Dawn, and R. Bolli Delayed adaptation of the heart to stress: late preconditioning Stroke 35 2004 2676 2679
24. P.D. Lambiase, R.J. Edwards, M.R. Cusack, C.A. Bucknall, S.R. Redwood, and M.S. Marber Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment J. Am. Coll. Cardiol. 41 2003 1174 1182
25. M.C. Luca, A. Liuni, K. McLaughlin, T. Gori, and J.D. Parker Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: a human study J. Am. Heart Assoc. 2 2013 e000075
26. E. Murphy, and C. Steenbergen Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury Physiol. Rev. 88 2008 581 609
27. K. Przyklenk, B. Bauer, M. Ovize, R.A. Kloner, and P. Whittaker Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion Circulation 87 1993 893 899
28. D.J. Hausenloy, and D.M. Yellon Remote ischaemic preconditioning: underlying mechanisms and clinical application Cardiovasc. Res. 79 2008 377 386
29. Z.Q. Zhao, J.S. Corvera, M.E. Halkos, F. Kerendi, N.P. Wang, and R.A. Guyton Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning Am. J. Physiol. Heart Circ. Physiol. 285 2003 H579 H588
30. W.K. Laskey, and A. Schevchuck Postconditioning during percutaneous coronary intervention in acute myocardial infarction: continued difficulty in translation Circulation 128 2013 1858 1860
31. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, and H.D. White Third universal definition of myocardial infarction J. Am. Coll. Cardiol. 60 2012 1581 1598
32. S.P. Hoole, P.M. Heck, L. Sharples, S.N. Khan, R. Duehmke, and C.G. Densem Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial Circulation 119 2009 820 827
33. W.R. Davies, A.J. Brown, W. Watson, L.M. McCormick, N.E. West, and D.P. Dutka Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up Circ. Cardiovasc. Interv. 6 2013 246 251
34. S.J. Luo, Y.J. Zhou, D.M. Shi, H.L. Ge, J.L. Wang, and R.F. Liu Remote ischemic preconditioning reduces myocardial injury in patients undergoing coronary stent implantation Can. J. Cardiol. 29 2013 1084 1089
35. H.E. Botker, R. Kharbanda, M.R. Schmidt, M. Bottcher, A.K. Kaltoft, and C.J. Terkelsen Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial Lancet 375 2010 727 734
36. I. Rentoukas, G. Giannopoulos, A. Kaoukis, C. Kossyvakis, K. Raisakis, and M. Driva Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action JACC Cardiovasc. Interv. 3 2010 49 55
37. P. Sorensson, N. Saleh, F. Bouvier, F. Bohm, M. Settergren, and K. Caidahl Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction Heart 96 2010 1710 1715
38. X. Freixa, N. Bellera, J.T. Ortiz-Perez, M. Jimenez, C. Pare, and X. Bosch Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary intervention Eur. Heart J. 33 2012 103 112
39. P. Staat, G. Rioufol, C. Piot, Y. Cottin, T.T. Cung, and I. L'Huillier Postconditioning the human heart Circulation 112 2005 2143 2148
40. H. Thibault, C. Piot, P. Staat, L. Bontemps, C. Sportouch, and G. Rioufol Long-term benefit of postconditioning Circulation 117 2008 1037 1044
41. A. Schevchuck, and W.K. Laskey Ischemic conditioning as an adjunct to percutaneous coronary intervention Circ. Cardiovasc. Interv. 6 2013 484 492
42. J.Y. Hahn, Y.B. Song, E.K. Kim, C.W. Yu, J.W. Bae, and W.Y. Chung Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial Circulation 128 2013 1889 1896
43. L. Argaud, O. Gateau-Roesch, D. Muntean, L. Chalabreysse, J. Loufouat, and D. Robert Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury J. Mol. Cell. Cardiol. 38 2005 367 374
44. C. Piot, P. Croisille, P. Staat, H. Thibault, G. Rioufol, and N. Mewton Effect of cyclosporine on reperfusion injury in acute myocardial infarction N. Engl. J. Med. 359 2008 473 481
45. R.R. Morrison, X.L. Tan, C. Ledent, S.J. Mustafa, and P.A. Hofmann Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postconditioning Am. J. Physiol. Heart Circ. Physiol. 293 2007 H2523 H2529
46. K.W. Mahaffey, J.A. Puma, N.A. Barbagelata, M.F. DiCarli, M.A. Leesar, and K.F. Browne Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial J. Am. Coll. Cardiol. 34 1999 1711 1720
47. A.M. Ross, R.J. Gibbons, G.W. Stone, R.A. Kloner, and R.W. Alexander A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) J. Am. Coll. Cardiol. 45 2005 1775 1780
48. R.A. Kloner, M.B. Forman, R.J. Gibbons, A.M. Ross, R.W. Alexander, and G.W. Stone Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial Eur. Heart J. 27 2006 2400 2405
49. W. Desmet, J. Bogaert, C. Dubois, P. Sinnaeve, T. Adriaenssens, and C. Pappas High-dose intracoronary adenosine for myocardial salvage in patients with acute ST-segment elevation myocardial infarction Eur. Heart J. 32 2011 867 877
50. J.E. Schultz, A.K. Hsu, and G.J. Gross Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart Circ. Res. 78 1996 1100 1104
51. G.T. Wong, Z. Huang, S. Ji, and M.G. Irwin Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial J. Cardiothorac. Vasc. Anesth. 24 2010 790 796
52. J. Imagawa, G.F. Baxter, and D.M. Yellon Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo J. Cardiovasc. Pharmacol. 31 1998 74 79
53. M. Wu, Z. Huang, H. Xie, and Z. Zhou Nicorandil in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis PLoS One 8 2013 e78231
54. S. Yusuf, R. Collins, S. MacMahon, and R. Peto Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials Lancet 1 1988 1088 1092
55. B.I. Jugdutt Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108 2003 1395 1403
56. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr., and T.E. Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N. Engl. J. Med. 327 1992 669 677
57. B.I. Jugdutt, A. Jelani, A. Palaniyappan, H. Idikio, R.E. Uweira, and V. Menon Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker Circulation 122 2010 341 351
58. P.F. Kantor, A. Lucien, R. Kozak, and G.D. Lopaschuk The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase Circ. Res. 86 2000 580 588
59. I. Maridonneau-Parini, and C. Harpey Trimetazidine protects the human red blood cell against oxygen free radical damage Cardiovasc. Drugs Ther. 4 Suppl. 4 1990 818 819
60. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project - Free Radicals Eur. Heart J. 21 2000 1537 1546
61. L. Bonello, P. Sbragia, N. Amabile, O. Com, S.V. Pierre, and S. Levy Protective effect of an acute oral loading dose of trimetazidine on myocardial injury following percutaneous coronary intervention Heart 93 2007 703 707
62. J.T. Flaherty, B. Pitt, J.W. Gruber, R.R. Heuser, D.A. Rothbaum, and L.R. Burwell Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction Circulation 89 1994 1982 1991
63. R. Rodrigo, J.C. Prieto, and R. Castillo Cardioprotection against ischaemia/reperfusion by vitamins C and E plus n-3 fatty acids: molecular mechanisms and potential clinical applications Clin. Sci. (Lond.) 124 2013 1 15
64. K. Tsovolas, E.K. Iliodromitis, I. Andreadou, A. Zoga, M. Demopoulou, and K.E. Iliodromitis Acute administration of vitamin C abrogates protection from ischemic preconditioning in rabbits Pharmacol. Res. 57 2008 283 289
65. P.W. Armstrong, C.B. Granger, P.X. Adams, C. Hamm, D. Holmes Jr., and W.W. O'Neill Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 2007 43 51
66. M.R. Patel, S.G. Worthley, A. Stebbins, T. Dill, F.E. Rademakers, and U.S. Valeti Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial JACC Cardiovasc. Imaging 3 2010 52 60
67. G. Vilahur, L. Casani, E. Pena, X. Duran, O. Juan-Babot, and L. Badimon Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction Atherosclerosis 206 2009 95 101
68. J.S. Kim, J. Kim, D. Choi, C.J. Lee, S.H. Lee, and Y.G. Ko Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial JACC Cardiovasc. Interv. 3 2010 332 339
69. D.E. Winchester, X. Wen, L. Xie, and A.A. Bavry Evidence of pre-procedural statin therapy a meta-analysis of randomized trials J. Am. Coll. Cardiol. 56 2010 1099 1109
70. R.M. Mentzer Jr., C. Bartels, R. Bolli, S. Boyce, G.D. Buckberg, and B. Chaitman Sodium-hydrogen exchange inhibition by cariporide to reduce the risk of ischemic cardiac events in patients undergoing coronary artery bypass grafting: results of the EXPEDITION study Ann. Thorac. Surg. 85 2008 1261 1270
71. F. Pelliccia, V. Pasceri, G. Marazzi, G. Rosano, C. Greco, and C. Gaudio A pilot randomized study of ranolazine for reduction of myocardial damage during elective percutaneous coronary intervention Am. Heart J. 163 2012 1019 1023
72. D.A. Morrow, B.M. Scirica, E. Karwatowska-Prokopczuk, S.A. Murphy, A. Budaj, and S. Varshavsky Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA 297 2007 1775 1783
73. K. Malmberg, L. Ryden, S. Efendic, J. Herlitz, P. Nicol, and A. Waldenstrom Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J. Am. Coll. Cardiol. 26 1995 57 65
74. K. Malmberg, L. Ryden, H. Wedel, K. Birkeland, A. Bootsma, and K. Dickstein Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Eur. Heart J. 26 2005 650 661
75. R.A. Kloner, and R.W. Nesto Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection Circulation 117 2008 2523 2533
76. H.P. Selker, J.R. Beshansky, P.R. Sheehan, J.M. Massaro, J.L. Griffith, and R.B. D'Agostino Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial JAMA 307 2012 1925 1933
77. J.J. Holst The physiology of glucagon-like peptide 1 Physiol. Rev. 87 2007 1409 1439
78. A.K. Bose, M.M. Mocanu, R.D. Carr, C.L. Brand, and D.M. Yellon Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury Diabetes 54 2005 146 151
79. P.A. Read, F.Z. Khan, P.M. Heck, S.P. Hoole, and D.P. Dutka DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease Circ. Cardiovasc. Imaging 3 2010 195 201
80. P.A. Read, S.P. Hoole, P.A. White, F.Z. Khan, M. O'Sullivan, and N.E. West A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans Circ. Cardiovasc. Interv. 4 2011 266 272
81. J. Lonborg, N. Vejlstrup, H. Kelbaek, H.E. Botker, W.Y. Kim, and A.B. Mathiasen Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction Eur. Heart J. 33 2012 1491 1499
82. J.S. Woo, W. Kim, S.J. Ha, J.B. Kim, S.J. Kim, and W.S. Kim Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study Arterioscler. Thromb. Vasc. Biol. 33 2013 2252 2260
83. R. Tissier, B. Ghaleh, M.V. Cohen, J.M. Downey, and A. Berdeaux Myocardial protection with mild hypothermia Cardiovasc. Res. 94 2012 217 225
84. W.W. O'Neill, S.R. Dixon, and C.L. Grines The year in interventional cardiology J. Am. Coll. Cardiol. 45 2005 1117 1134
85. D. Erlinge, M. Gotberg, C. Grines, S. Dixon, K. Baran, and D. Kandzari A pooled analysis of the effect of endovascular cooling on infarct size in patients with ST-elevation myocardial infarction EuroIntervention 8 2013 1435 1440
86. D. Erlinge, M. Gotberg, I. Lang, M. Holzer, M. Noc, and P. Clemmensen Rapid endovascular catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction. The CHILL-MI trial: a randomized controlled study of the use of central venous catheter core cooling combined with cold saline as an adjunct to percutaneous coronary intervention for the treatment of acute myocardial infarction J. Am. Coll. Cardiol. 63 2014 1857 1865
87. C. Testori, F. Sterz, G. Delle-Karth, R. Malzer, M. Holzer, and P. Stratil Strategic target temperature management in myocardial infarction - a feasibility trial Heart 99 2013 1663 1667
88. H.J. Whittington, I. Harding, C.I. Stephenson, R. Bell, D.J. Hausenloy, and M.M. Mocanu Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling Cardiovasc. Res. 99 2013 694 704
89. A. Tsang, D.J. Hausenloy, M.M. Mocanu, R.D. Carr, and D.M. Yellon Preconditioning the diabetic heart: the importance of Akt phosphorylation Diabetes 54 2005 2360 2364
90. G. Heusch Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur. Heart J. 2012 13 15 (England)
91. H. Kin, Z.Q. Zhao, H.Y. Sun, N.P. Wang, J.S. Corvera, and M.E. Halkos Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion Cardiovasc. Res. 62 2004 74 85
92. F. Thuny, O. Lairez, F. Roubille, N. Mewton, G. Rioufol, and C. Sportouch Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction J. Am. Coll. Cardiol. 59 2012 2175 2181
93. M. Ovize, H. Thibault, and K. Przyklenk Myocardial conditioning: opportunities for clinical translation Circ. Res. 113 2013 439 450
94. J. Lonborg, H. Kelbaek, N. Vejlstrup, E. Jorgensen, S. Helqvist, and K. Saunamaki Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance Circ. Cardiovasc. Interv. 3 2010 34 41
95. C.M. Zhao, X.J. Yang, J.H. Yang, X.J. Cheng, X. Zhao, and B.Y. Zhou Effect of ischaemic postconditioning on recovery of left ventricular contractile function after acute myocardial infarction J. Int. Med. Res. 40 2012 1082 1088
96. M.L. Fokkema, P.J. Vlaar, M. Vogelzang, Y.L. Gu, M.A. Kampinga, and B.J. De Smet Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial Circ. Cardiovasc. Interv. 2 2009 323 329
97. K.W. Baran, M. Nguyen, G.R. McKendall, C.T. Lambrew, G. Dykstra, and S.T. Palmeri Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study Circulation 104 2001 2778 2783
98. C.B. Granger, K.W. Mahaffey, W.D. Weaver, P. Theroux, J.S. Hochman, and T.G. Filloon Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial Circulation 108 2003 1184 1190
99. D.P. Faxon, R.J. Gibbons, N.A. Chronos, P.A. Gurbel, and F. Sheehan The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study J. Am. Coll. Cardiol. 40 2002 1199 1204
100. J.-F. Tanguay, M.W. Krucoff, R.J. Gibbons, E. Chavez, A.S. Liprandi, and V. Molina-Viamonte Efficacy of a novel P-selectin antagonist, rPSGL-Ig for reperfusion therapy in acute myocardial infarction: the RAPSODY trial J. Am. Coll. Cardiol. 41 2003 404 405
101. P. Mertens, A. Maes, J. Nuyts, A. Belmans, W. Desmet, and E. Esplugas Recombinant P-selectin glycoprotein ligand-immunoglobulin, a P-selectin antagonist, as an adjunct to thrombolysis in acute myocardial infarction. The P-Selectin Antagonist Limiting Myonecrosis (PSALM) trial Am. Heart J. 152 2006 125.e1-8
102. M. Gotberg, G.K. Olivecrona, S. Koul, M. Carlsson, H. Engblom, and M. Ugander A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction Circ. Cardiovasc. Interv. 3 2010 400 407
103. D. Erlinge CHILL-MI. A Prospective, Randomised Trial of Therapeutic Hypothermia in Patients with Acute Myocardial Infarction Undergoing Primary PCI. Transcatheter Cardiovascular Therapeutics 2013 (San Francisco, CA. USA)
104. H. Ishii, S. Ichimiya, M. Kanashiro, T. Amano, K. Imai, and T. Murohara Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction Circulation 112 2005 1284 1288
105. M. Kitakaze, M. Asakura, J. Kim, Y. Shintani, H. Asanuma, and T. Hamasaki Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials Lancet 370 2007 1483 1493
106. U. Zeymer, H. Suryapranata, J.P. Monassier, G. Opolski, J. Davies, and G. Rasmanis The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial J. Am. Coll. Cardiol. 38 2001 1644 1650